SummaryRMgm-300
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 17583362 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei NK65 |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | L. Bethke, D. Wirth |
Name Group/Department | Department of Immunology and Infectious Diseases |
Name Institute | Harvard School of Public Health |
City | Boston |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-300 |
Principal name | PbMSH2-2 mutant (clone A2, B2) |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Not different from wild type |
Liver stage | Not different from wild type |
Additional remarks phenotype | Mutant/mutation |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0804300 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0706700 | ||||||||||||||||||||||||
Gene product | DNA mismatch repair protein MSH2, putative | ||||||||||||||||||||||||
Gene product: Alternative name | MSH2-2 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid single cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | XcmI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption |
The plasmid designed to disrupt PbMSH2-2 included as a target sequence for homologous recombination, a 1380 bp fragment of PbMSH2-2, which lacked sequence encoding the first 127 amino acids of the protein, including a portion of the putative DNA binding domain, and was also missing the C-terminal 269 amino acids, including the ATP binding domain and the mutS signature motif. The insertion plasmid was designed to integrate via a single crossover event, resulting in two truncated copies of the gene. No information is provided on the sequence of the primers used to amplify the target sequence for homologous recombination. | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The plasmid designed to disrupt PbMSH2-2 included as a target sequence for homologous recombination, a 1380 bp fragment of PbMSH2-2, which lacked sequence encoding the first 127 amino acids of the protein, including a portion of the putative DNA binding domain, and was also missing the C-terminal 269 amino acids, including the ATP binding domain and the mutS signature motif. The insertion plasmid was designed to integrate via a single crossover event, resulting in two truncated copies of the gene. No information is provided on the sequence of the primers used to amplify the target sequence for homologous recombination. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |